

Biocon Biologics Switzerland AG**BALANCE SHEET AS AT MARCH 31, 2025**

(All amounts in CHF Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	March 31, 2025	March 31, 2024
ASSETS			
Current assets			
Inventories	1	1,087	921
Financial assets			
(i) Trade receivables	2	268	263
(ii) Cash and cash equivalents	3	180	441
Other current assets	4	1	-
Total current assets		1,536	1,625
TOTAL		1,536	1,662
EQUITY AND LIABILITIES			
Equity			
Equity share capital	5	50	50
Other equity	6	67	10
Total equity		117	60
Current liabilities			
Financial liabilities			
(i) Trade payables	7	1,156	1,504
(ii) Other financial liabilities			
Income-tax liability (net)		16	2
Provisions	8	47	19
Other current liabilities	9	200	40
Total current liabilities		1,419	1,602
TOTAL		1,536	1,662

Biocon Biologics Switzerland AG**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2025**

(All amounts in CHF Thousands, except share data and unless otherwise stated)

		Year ended	Period ended
	<u>Notes</u>	March 31, 2025	March 31, 2024
<hr/>			
Income			
Revenue from operations	10	1,734	591
Other operating income	11	245	-
Total revenue (I)		<hr/> 1,979	<hr/> 591
Expenses			
Purchases of traded goods	12	(223)	79
Changes in inventories of traded goods	13	(166)	117
Employee benefits expense	14	1,747	281
Other expenses	15	550	102
Total expenses (II)		<hr/> 1,908	<hr/> 579
Profit before tax		<hr/> 71	<hr/> 12
Tax expense			
Current tax		(23)	2
Deferred Tax		37	-
Total tax expense		<hr/> 14	<hr/> 2
Profit for the year		<hr/> 57	<hr/> 10

Biocon Biologics Switzerland AG
STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31, 2025

(All amounts in CHF Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2025	Period ended March 31, 2024
I Cash flows from operating activities		
Profit after tax	57	10
<u>Adjustments to reconcile profit before tax to net cash flows:</u>		
Tax expense	14	2
Operating profit before working capital changes	71	12
Movements in working capital		
(Increase) in trade receivables	(5)	(263)
(Increase) in trade inventories	(166)	(921)
(Increase) in loans and advances and other assets	(1)	-
(Decrease) /Increase in trade payable, other liabilities and provisions	(160)	1,563
Cash generated from/(used in) operations	(261)	391
Direct taxes paid	-	-
Net cash flow (used in) /generated from operating activities	(261)	391
III Cash flows from financing activities		
Proceeds from issue of equity shares	-	50
Net cash flow generated from financing activities	-	50
IV Net increase/(decrease) in cash and cash equivalents (I + II + III)	(261)	441
VI Cash and cash equivalents at the beginning of the year	441	-
VIII Cash and cash equivalents at the end of the period (IV + V + VI)	180	441
Reconciliation of cash and cash equivalents as per statement of cash flow		
Cash and cash equivalents		
Balances with banks - on current accounts	180	441
	180	441
Total cash and cash equivalents [Refer note 3]	180	441

Biocon Biologics Switzerland AG**Notes to financial statements for the year ended 'March 31, 2025**

(All amounts in CHF Thousands, except share data and unless otherwise stated)

	March 31, 2025	March 31, 2024
1. Inventories		
Finished Goods	1,087	921
	1,087	921
2. Trade receivables		
Other Receivables		
Outstanding for a period less than six months from the date they are due for payment		
Unsecured, considered good	268	263
	268	263
3. Cash and cash equivalents		
Balances with banks:		
On current accounts	180	441
	180	441
4. Other current assets		
Prepayments	1	-
	1	-
5. Share capital		
100,000 Equity share of CHF 0.5 each	50	50
	50	50
6. Other equity		
Surplus/(deficit) in the statement of profit and loss		
Balance as per the last financial statements	10	-
Profit for the year	57	10
Net surplus in the statement of profit and loss	67	10
Total other equity	67	20
7. Trade payables	1,156	1,504
8. Provisions		
Current		
Compensated absences	47	19
	47	19
9. Other liabilities		
Current liabilities		
Statutory liabilities	200	40
	200	40

Biocon Biologics Switzerland AG**Notes to financial statements for the year ended 'March 31, 2025**

(All amounts in CHF Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2025	Period ended March 31, 2024
10. Revenue from operations		
Sale of Products		
Traded Goods	1,498	591
Sale of Services		
Support service cross charge to Group Companies	236	-
	1,734	591
11. Other operating income		
Foreign exchange fluctuations, net	(9)	-
Support service cross charge to Group Companies	254	-
	245	-
12. Purchase of traded goods	(223)	79
	(223)	79
13. Changes in inventories of traded goods		
Inventory at the beginning of the year		
Traded goods	921	-
Inventory Transfer during the year		
Traded goods	-	1,038
Inventory at the end of the year		
Traded goods	1,087	921
	(166)	117

Biocon Biologics Switzerland AG**Notes to financial statements for the year ended 'March 31, 2025**

(All amounts in CHF Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2025	Period ended March 31, 2024
14. Employee benefits expense		
Salaries, wages and bonus	1,479	275
Contribution to Defined Cont'n Plan	148	-
Employee stock compensation expense	120	-
Staff welfare expenses	-	6
	1,747	281
15. Other expenses		
Rent	5	1
Legal and professional fees	261	1
Travelling and conveyance	64	5
Selling expenses		
Sales promotion expenses	56	89
Distribution Expenses	98	-
Printing and stationery	14	-
Communication expenses	4	1
Miscellaneous expenses	46	5
Insurance Charges	2	-
	550	102